Latest / Stock Movers / Monte Dei Paschi Up, Tate & Lyle Out, Zealand Pharma Down
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, Podcasts, radio News, The.
- 0:08Speaker 2: Stock Movers report, your roundup of companies making moves in
- 0:12Speaker 2: the stock market, harnessing the power of Bloomberg data, and.
- 0:16Speaker 3: Look at some of the stocks on the move today
- 0:18Speaker 3: in Europe. I'm to you Ada Bay with Stephen Carroll
- 0:21Speaker 3: and we're joined by Bloomberg's Breaking News editor Louise Mean
- 0:24Speaker 3: Louise Monte de Pasci seems to be very popular this morning.
- 0:28Speaker 3: It's being inundated with offers. Can you tell us more
- 0:30Speaker 3: about what's going on there?
- 0:31Speaker 2: It is?
- 0:32Speaker 1: Indeed, yes, I'll start with the most recent one. So Intesa,
- 0:34Speaker 1: the other Italian bank, has offered to buy Montepasti, So
- 0:38Speaker 1: that would if you know, if that all came through
- 0:40Speaker 1: and came to fruition, that would boost Intesa's position as
- 0:44Speaker 1: the largest lender in itlay would also create one of
- 0:47Speaker 1: Europe's most valuable banks. So that's one of the offers
- 0:50Speaker 1: that it's had. That it comes a day after a
- 0:52Speaker 1: separate offer from Banco BPM, also of course an Italian bank.
- 0:56Speaker 1: They pitched what they're calling a merger of equals so
- 1:00Speaker 1: to combine, and the combined group would be worth about
- 1:04Speaker 1: fifty billion euros in total. So an interesting note from
- 1:09Speaker 1: Blueberg Intelligence saying in Tessa's offer is more advanced and
- 1:12Speaker 1: binding than Banco BPMS and therefore is putting pricing pressure
- 1:16Speaker 1: on Banco. So who knows, maybe a bit of a
- 1:20Speaker 1: kind of bidding wall will play out. That's kind of
- 1:23Speaker 1: waiting to be seen. But at the moment, Monte Dee
- 1:25Speaker 1: Pascual shares jumping as much as ten percent this morning
- 1:28Speaker 1: to the highest since twenty twenty two. Obviously, any deal
- 1:31Speaker 1: is going to have bigger implications in the Italian banking sector,
- 1:34Speaker 1: adding to a flurry of activity we've been seeing in
- 1:36Speaker 1: recent years already in that sector. So we're going to
- 1:39Speaker 1: be keeping a close eye. And that's some really interesting
- 1:42Speaker 1: activity playing out there.
- 1:45Speaker 2: And in London the Stock Exchange missing out on a
- 1:48Speaker 2: sweet deal.
- 1:49Speaker 1: Indeed, we're well London, it is losing Tait and Lyle,
- 1:53Speaker 1: obviously known as one of Britain's biggest, oldest, largest suitet
- 1:59Speaker 1: relation firms. So it's being bought by the US rival
- 2:02Speaker 1: Ingredient for two point seven billion pounds. That's been agreed
- 2:07Speaker 1: and as you say, it's it's another big name leaving
- 2:12Speaker 1: London Stock Exchange. If this happens. So the offer is
- 2:16Speaker 1: six hundred and fifteen pence per share in values that's
- 2:19Speaker 1: mostly in cash and then the rest is in dividends.
- 2:21Speaker 1: That represents a sixty percent premium to take and allows
- 2:25Speaker 1: share price before the news of a possible deal broke
- 2:27Speaker 1: last month. So since then shares a risen about thirty
- 2:30Speaker 1: one percent and then this morning more as much as
- 2:33Speaker 1: thirteen percent. They're still, however, trading below the offer price.
- 2:36Speaker 1: From Ingredients and Less are saying, you know, it's a
- 2:39Speaker 1: good deal. There's little risk of another bidder emerging, but
- 2:43Speaker 1: there is still some risk around it that regulatory approval
- 2:47Speaker 1: maybe would not be given given competition concerns. So it's
- 2:50Speaker 1: been agreed but still has to go through. So yeah,
- 2:54Speaker 1: shares rising today and if it all goes through, another
- 2:57Speaker 1: big London name leaving the stock change as we've been
- 3:00Speaker 1: seeing in recent years.
- 3:02Speaker 3: Okay, perhaps waiting a sweet escape there for Taita Lyle,
- 3:06Speaker 3: but moving to pharmaceuticals in the zeal And, farmer are
- 3:10Speaker 3: being weighed down by some poor drug results.
- 3:13Speaker 2: Yeah.
- 3:13Speaker 1: So based in Copenhagen, the biotech company said shares stumbling
- 3:16Speaker 1: this morning as much as twenty six percent over in
- 3:19Speaker 1: Copenhagen for Zealand Farmer. So they had results for two
- 3:22Speaker 1: experimental obesity drugs. Neither were great essentially, so one of
- 3:27Speaker 1: them a lot of patients discontinued the trial because of
- 3:32Speaker 1: gasher intestinal events so nausea, vomiting, all of that. Analystser
- 3:35Speaker 1: noting that that drug in particular is notably worse than
- 3:39Speaker 1: rival obesity drugs. And then another one for the second trial,
- 3:43Speaker 1: showed less weight loss than Eli Lilly's drugs, so that's
- 3:46Speaker 1: obviously one of their main rivals over in the US.
- 3:48Speaker 1: So total together, essentially there's concern about Zealand Farmer's ability
- 3:54Speaker 1: to compete. It's a crowded market in the weight loss
- 3:57Speaker 1: drug space, very competitive. You've got Eli Lilly and a
- 4:00Speaker 1: host of other companies. So these poor results from these
- 4:03Speaker 1: two trials aren't very reassuring essentially, as I say, shares
- 4:08Speaker 1: tumbling on the.
- 4:08Speaker 2: Back of that. The Stockmover's report from Bloomberg Radio. Check
- 4:13Speaker 2: back with us throughout the day for the latest roundup
- 4:16Speaker 2: of companies making news on Wall Street and for the
- 4:19Speaker 2: latest market moving headlines. Listen to Bloomberg Radio Live, catch
- 4:23Speaker 2: us on YouTube, Bloomberg dot com, and on Applecarplay and
- 4:27Speaker 2: Android Auto with the Bloomberg Business App.